<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35535703</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1473-0790</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>The aging male : the official journal of the International Society for the Study of the Aging Male</Title>
          <ISOAbbreviation>Aging Male</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy of pelvic floor muscle exercise or therapy with or without duloxetine: a systematic review and network Meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>145</StartPage>
          <EndPage>155</EndPage>
          <MedlinePgn>145-155</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13685538.2022.2069238</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Postprostatectomy urinary incontinence (PPUI) is a serious complication despite surgical advances. Treatment options for PPUI include conservative care like Pelvic floor muscle exercise (PFME), which is a physiotherapy performed by the patients themselves; Pelvic floor muscle therapy (PFMT), a physiotherapy performed under the guidance of a therapist, and duloxetine treatment; and surgical interventions. In this study, network meta-analysis (NMA) was performed for direct comparison of these treatment options.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">The NMA pooled the odds ratios and 95% credible intervals using the number of patients achieving urinary continence and the total number of patients in an intention-to-treat population. The treatments were ranked based on the surface under the cumulative ranking curve (SUCRA) probabilities and the rankograms.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The pooled overall ORs of patients achieving urinary continence compared with no treatment was 1.73 (95% CrI: 0.657, 4.71) in PFME, 2.62 (95% CrI: 0.553, 13.5) in PFME plus Duloxetine, and 4.05 (95% CrI: 1.70, 10.2) in PFMT. The SUCRA values of ranking probabilities for each treatment showed high rates of continence in the order of PFMT, PFME plus Duloxetine, and PFME.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The results suggest that patients with PPUI should undergo PFMT and consider duloxetine as an additional treatment option.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Jae Joon</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwon</LastName>
            <ForeName>Allison</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>College of Biological Science, University of California, Davis, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Noh</LastName>
            <ForeName>Tae Il</ForeName>
            <Initials>TI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Korea University Anam Hospital, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gwon</LastName>
            <ForeName>Yong Nam</ForeName>
            <Initials>YN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shim</LastName>
            <ForeName>Sung Ryul</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health and Medical Informatics, Kyungnam University College of Health Sciences, Changwon, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Jae Heon</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Aging Male</MedlineTA>
        <NlmUniqueID>9808210</NlmUniqueID>
        <ISSNLinking>1368-5538</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>9044SC542W</RegistryNumber>
          <NameOfSubstance UI="D000068736">Duloxetine Hydrochloride</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000068736" MajorTopicYN="N">Duloxetine Hydrochloride</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005081" MajorTopicYN="N">Exercise Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071076" MajorTopicYN="N">Network Meta-Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017773" MajorTopicYN="Y">Pelvic Floor</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014549" MajorTopicYN="Y">Urinary Incontinence</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Prostatectomy</Keyword>
        <Keyword MajorTopicYN="N">duloxetine</Keyword>
        <Keyword MajorTopicYN="N">pelvic floor</Keyword>
        <Keyword MajorTopicYN="N">postoperative complications</Keyword>
        <Keyword MajorTopicYN="N">urinary incontinence</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35535703</ArticleId>
        <ArticleId IdType="doi">10.1080/13685538.2022.2069238</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
